BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 18453724)

  • 1. The first pharmacoepidemiologic investigations: national drug safety policy in the United States, 1901-1902.
    Lilienfeld DE
    Perspect Biol Med; 2008; 51(2):188-98. PubMed ID: 18453724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allied against reform: pharmaceutical industry-academic physician relations in the United States, 1945-1970.
    Tobbell DA
    Bull Hist Med; 2008; 82(4):878-912. PubMed ID: 19075387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, supply, and suits--litigation and the vaccine industry.
    Kesselheim A
    N Engl J Med; 2011 Apr; 364(16):1485-7. PubMed ID: 21506740
    [No Abstract]   [Full Text] [Related]  

  • 5. Diphtheria serum and serotherapy. Development, production and regulation in fin de siècle Germany.
    Hüntelmann AC
    Dynamis; 2007; 27():107-31. PubMed ID: 18351161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Developments in the Regulation of Biologics.
    Coleman TS
    Food Drug Law J; 2016; 71(4):544-607. PubMed ID: 29140646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triage in the nation's medicine cabinet: the puzzling scarcity of vaccines and other drugs.
    Noah L
    S C Law Rev; 2002; 54(2):371-403. PubMed ID: 15156891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The Brazilian pharmaceutical market and the North American war effort].
    Quintaneiro T
    Estud Hist; 2002; (29):141-64. PubMed ID: 18030707
    [No Abstract]   [Full Text] [Related]  

  • 9. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 10. The origin of the production of diphtheria antitoxin in France, between philanthropy and commerce.
    Simon J
    Dynamis; 2007; 27():63-82. PubMed ID: 18351159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The drug that launched a thousand sleds.
    Scheindlin S
    Mol Interv; 2008 Aug; 8(4):152-8. PubMed ID: 18829839
    [No Abstract]   [Full Text] [Related]  

  • 12. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Watson KT; Barash PG
    Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-to-consumer genetic tests, government oversight, and the First Amendment: what the government can (and can't) do to protect the public's health.
    Javitt GH; Stanley E; Hudson K
    Oklahoma Law Rev; 2004; 57(2):251-302. PubMed ID: 15658034
    [No Abstract]   [Full Text] [Related]  

  • 14. Food and Drug Administration regulation and evaluation of vaccines.
    Marshall V; Baylor NW
    Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Paul Ehrlich and commercial serum production: on the control of diphtheria antitoxin in the laboratory and in industry].
    Hardy AI
    Medizinhist J; 2006; 41(1):51-84. PubMed ID: 16700300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rights, patents, markets and the global AIDS pandemic.
    Gathii JT
    Fla J Int Law; 2002; 14(2):261-352. PubMed ID: 16526139
    [No Abstract]   [Full Text] [Related]  

  • 17. The 1901 St Louis incident: the first modern medical disaster.
    DeHovitz RE
    Pediatrics; 2014 Jun; 133(6):964-5. PubMed ID: 24864186
    [No Abstract]   [Full Text] [Related]  

  • 18. The case for regulatory reform in the business and healthcare environments.
    Younis MZ; Barhem B; Hamidi S; Inungu J; Prater GS; O'Keefe A
    J Health Hum Serv Adm; 2009; 32(3):324-41. PubMed ID: 20099583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The Stalinon scandal and its regulatory consequences, 1954-1959. Drug safety and therapeutic innovation in France fifty years back].
    Bonah C
    Rev Prat; 2007 Sep; 57(13):1501-5. PubMed ID: 18018550
    [No Abstract]   [Full Text] [Related]  

  • 20. Adequate controls for new drugs: good manufacturing practice and the 1938 federal Food, Drug, and Cosmetic Act.
    Cooper DE
    Pharm Hist; 2002; 44(1):12-23. PubMed ID: 12068915
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.